Rosemary essential oil nanoparticles enhance antimicrobial activity and induce bacterial DNA disruption
International Microbiology · 2026
DOI: 10.1007/s10123-026-00815-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Microbiology, 2026. Verfasst von Habiba A Ahmed und 3 weiteren Autor:innen. Beteiligte Einrichtung: Plant Biochemistry Department, National Research Centre, Dokki, 12622, Giza, Egypt. Hauptthemen laut MEDLINE: Oils, Volatile, Nanoparticles, Bacteria, Anti-Infective Agents. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The current work aimed to formulate Rosemary essential oil nanoparticles (Ros-ES-NPs) and evaluate their antimicrobial effect in comparison with free oil (Ros- ES). Physicochemical characterization was performed using Fourier-transform infrared spectroscopy (FTIR), dynamic light scattering, zeta potential analysis, transmission electron microscop y (TEM), scanning electron microscopy (SEM), and thermogravimetric analysis (TGA). The cytotoxic activity of Ros-ES-NPs on human lung fibroblast cell line (Wi-38) was examined in comparison with Ros- ES using MTT assay. Ros-ES exhibited dose-dependent cytotoxicity, with an IC 50 of approximately 6.06 mg/ml on Wi-38. In contrast, the Ros-ES-NPs not only showed no toxicity but actually appeared to increase cell viability (up to ≈ 136%) possibly due to high metabolic actvity. The antimicrobial activity of Ros-ES and Ros-ES-NPs was evaluated against three isolates of Multidrug-Resistant Bacteria, comprising two Gram-negative isolates ( Shigella flexneri and Klebsiella pneumoniae ) and one Gram-positive isolate ( Streptococcus pneumoniae ), alongside C andida albicans as the fungal pathogen. Ros-ES-NPs showed a significant antimicrobial efficacy against all isolates under study where, at 25 mg/ml, Ros-ES inhibited K. pneumoniae and Shigella flexneri by 55.16 ± 0.09% and 76.47 ± 1.16%, respectively, whereas Ros-ES-NPs showed inhibition rates of 95.66 ± 9.74% and 87.13 ± 2.63%, respectively. Against Streptococcus pneumoniae , at 25 mg/ml, Ros-ES inhibited by 68.75 ± 0.60%, while Ros-ES-NPs exhibited a higher inhibition rate of 80.73 ± 5.6%. In case of C. albicans , Ros-Es showed a higher inhibition (81.85 ± 0.54) than Ros-Es-NPs (60.39 ± 5.69). Rosemary essential oil nano-formulation significantly enhances antibacterial efficacy while improving biocompatibility and inducing pronounced microbial DNA damage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Plant Biochemistry Department, National Research Centre, Dokki, 12622, Giza, Egypt.
- Medical Biotechnology Department, Genetic Engineering and Biotechnology Institute, City of Scientific Research and Technological Applications (SRTA-City), New Borg EL-Arab, Alexandria, 21934, Egypt.
- Medical Biotechnology Department, Genetic Engineering and Biotechnology Institute, City of Scientific Research and Technological Applications (SRTA-City), New Borg EL-Arab, Alexandria, 21934, Egypt. halaeladawi@hotmail.…
- Pharmaceutical and Fermentation Industries Development Center, City of Scientific Research and Technological Applications (SRTA-City), New Borg EL-Arab, Alexandria, 21934, Egypt.
Zitieren
APA
Ahmed, H. A., El-Adawi, H., Abdel-Fattah, A., & Abd El-Wahab, A. E. (2026). Rosemary essential oil nanoparticles enhance antimicrobial activity and induce bacterial DNA disruption. International Microbiology. https://doi.org/10.1007/s10123-026-00815-2
Vancouver
Ahmed HA, El-Adawi H, Abdel-Fattah A, Abd El-Wahab AE. Rosemary essential oil nanoparticles enhance antimicrobial activity and induce bacterial DNA disruption. International Microbiology. 2026. doi:10.1007/s10123-026-00815-2
BibTeX
@article{Ahmed2026,
author = {Ahmed, Habiba A and El-Adawi, Hala and Abdel-Fattah, Asmaa and Abd El-Wahab, Abeer E},
title = {Rosemary essential oil nanoparticles enhance antimicrobial activity and induce bacterial DNA disruption},
journal = {International Microbiology},
year = {2026},
doi = {10.1007/s10123-026-00815-2}
}
EUVIMED